DelveInsight Business Research LLP

DelveInsight’s “Cystinosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Cystinosis pipeline landscapes. It comprises Cystinosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cystinosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cystinosis pipeline products.     

Some of the key takeaways of the Cystinosis Pipeline Report:

• Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, etc., are developing therapies for the treatment of Cystinosis.

• Emerging therapies such as Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), are expected to have a significant impact on the  Cystinosis market in the coming years.

• ELX-02 (formerly known as NB124) is a small molecule, administered by the parenteral subcutaneous (SC) route. The molecule is under investigation for the treatment of cystinosis. It is under Phase II clinical trial.

Get an overview of pipeline landscape @ Cystinosis Clinical Trials Analysis 

Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of cystine, the oxidized dimer of the amino acid cysteine. It is a genetic disorder that follows an autosomal recessive inheritance pattern.

For further information, refer to the detailed report @ Cystinosis Pipeline Therapeutics 

Cystinosis Emerging Drugs

• Procysbi (cysteamine bitartrate) by Horizon Pharma

• Cystadrops (cysteamine hydrochloride) by Recordati S.p.A.

• Cystaran (cysteamine hydrochloride) by Leadiant Biosciences

• Cystagon (cysteamine bitartrate) by Mylan Pharmaceuticals

Scope of Cystinosis Pipeline Drug Insight    

• Coverage: Global 

• Major Players: Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, and others.

• Pipeline Therapies: Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), and others.

Table of Contents

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/